Meeting Details

The Board meeting was held on Wednesday, August 12, 2026, commencing at 4:50 PM and concluding at 5:20 PM.

Financial Results Overview

Consolidated Financial Results (₹ in lakhs)

Quarter Ended June 30, 2026 (Unaudited) vs Comparative Periods:

  • Revenue from Operations: ₹13,916.28 (vs ₹10,418.54 in Q1 FY26; ₹14,923.28 in Q4 FY26)
  • Other Income: ₹742.81 (vs ₹635.35 in Q1 FY26; ₹245.92 in Q4 FY26)
  • Total Revenue: ₹14,659.09 (vs ₹11,053.89 in Q1 FY26; ₹15,169.20 in Q4 FY26)
  • Total Expenses: ₹12,211.42 (vs ₹9,869.94 in Q1 FY26; ₹13,387.95 in Q4 FY26)
  • Profit Before Tax: ₹2,447.68 (vs ₹1,183.95 in Q1 FY26; ₹1,781.25 in Q4 FY26)
  • Tax Expense: ₹607.96 (Current Tax: ₹445.00; Deferred Tax: ₹162.96)
  • Profit from Continuing Operations: ₹1,839.72 (vs ₹924.06 in Q1 FY26; ₹1,348.56 in Q4 FY26)
  • Other Comprehensive Income: ₹(36.08) (Net of Tax)
  • Total Comprehensive Income: ₹1,803.64 (vs ₹899.59 in Q1 FY26; ₹1,339.23 in Q4 FY26)
  • Basic EPS: ₹29.78 (vs ₹14.96 in Q1 FY26; ₹21.83 in Q4 FY26)
  • Diluted EPS: ₹29.78 (vs ₹14.96 in Q1 FY26; ₹21.83 in Q4 FY26)

Standalone Financial Results (₹ in lakhs)

Quarter Ended June 30, 2026 (Unaudited) vs Comparative Periods:

  • Revenue from Operations: ₹13,671.32 (vs ₹10,085.81 in Q1 FY26; ₹14,474.55 in Q4 FY26)
  • Other Income: ₹735.67 (vs ₹655.34 in Q1 FY26; ₹251.18 in Q4 FY26)
  • Total Revenue: ₹14,406.99 (vs ₹10,741.15 in Q1 FY26; ₹14,725.73 in Q4 FY26)
  • Total Expenses: ₹12,232.48 (vs ₹9,769.68 in Q1 FY26; ₹13,238.20 in Q4 FY26)
  • Profit Before Tax: ₹2,174.51 (vs ₹971.47 in Q1 FY26; ₹1,487.53 in Q4 FY26)
  • Tax Expense: ₹529.38 (Current Tax: ₹360.00; Deferred Tax: ₹169.38)
  • Profit from Continuing Operations: ₹1,645.13 (vs ₹764.41 in Q1 FY26; ₹1,135.42 in Q4 FY26)
  • Other Comprehensive Income: ₹(35.57) (Net of Tax)
  • Total Comprehensive Income: ₹1,609.56 (vs ₹740.30 in Q1 FY26; ₹1,128.03 in Q4 FY26)
  • Basic EPS: ₹26.63 (vs ₹12.37 in Q1 FY26; ₹18.38 in Q4 FY26)
  • Diluted EPS: ₹26.63 (vs ₹12.37 in Q1 FY26; ₹18.38 in Q4 FY26)

Capital Structure

Paid-up Equity Share Capital remains unchanged at ₹308.90 lakhs (Face Value: ₹5 per share) for both standalone and consolidated entities.

Business Segment Information

The company operates in a single business segment - pharmaceuticals - in accordance with Ind AS 108 "Operating Segments."

Subsidiary Information

The consolidated results include 100% subsidiary Macrotech Polychem Private Limited.

Auditor Review

The results were subjected to limited review by the statutory auditors, Manek & Associates (Firm Registration No.: 126679W), who issued an unmodified review conclusion stating that nothing has come to their attention that causes them to believe the financial results contain any material misstatement.

Approval Process

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 12, 2026.

Additional Notes

  • Figures for the quarter ended March 31, 2026, are balancing figures between audited annual figures and published year-to-date figures
  • Previous period figures have been regrouped/rearranged where necessary